Persistent viremia by a novel parvovirus in a slow loris (Nycticebus coucang) with diffuse histiocytic sarcoma

Marta Canuti1,*, Cathy V. Williams2, Sashi R. Gadi3, Maarten F. Jebbink1, Bas B. Oude Munnik1, Seyed Mohammad Jazaeri Farsani1,4, John M. Cullen3 and Lia van der Hoek1*

1 Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center of the University of Amsterdam, Amsterdam, Netherlands
2 Duke Lemur Center, Duke University, Durham, NC, USA
3 Department of Population Health and Pathobiology, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, USA
4 Department of Virology, Tehran University of Medical Sciences, Tehran, Iran

*Correspondence:
Marta Canuti, Department of Biology, Memorial University of Newfoundland, 232 Elizabeth Ave, St John’s, NL A1B 3X9, Canada
e-mail: marta.canuti@gmail.com; mcanuti@mun.ca;
Lia van der Hoek, Laboratory of Experimental Virology, Department of Medical Microbiology, Academic Medical Centre, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, Netherlands
e-mail: c.m.vanderhoek@amc.uva.nl
1 Present address:
Marta Canuti, Department of Biology, Memorial University of Newfoundland, St. John’s, Canada

INTRODUCTION
The Sunda slow loris (Nycticebus coucang), a Strepsirrhine primate which belongs to the family Lorisidae, is a nocturnal, arboreal prosimian species native to Indonesia (Sumatra), western Malaysia (Peninsular Malaysia), Singapore and southern Thailand (Nekaris and Streicher, 2008). Slow lorises, listed as a vulnerable species by the International Union for Conservation and Nature (IUCN) (IUCN Red List of Threatened Species, available at: www.iucnredlist.org), are protected by law in Malaysia, Thailand, and Indonesia since their conservation status is a matter of concern. The biggest threat endangering these animals is the pet trade—they are the most commonly protected primates species sold as exotic pets in southeast Asia (Nekaris and Nijman, 2007), but habitat loss and the fact they are killed as crop pests also jeopardize their survival (Nekaris and Streicher, 2008). Because of these reasons a better understanding of the causes and the dynamics of diseases in N. coucang is advantageous for conservation attempts and captive management of this species (Remick et al., 2009). In addition, valuable information can be gathered by the study of diseases in non-human primates, which in turn might be beneficial for human health.

We investigated a case of histiocytic sarcoma (HS) in a N. coucang identified at the Duke Lemur Center (DLC) in Durham, North Carolina. HS is a highly aggressive hematopoietic tumor defined as a malignant proliferation of cells showing morphological and immunophenotypic features of mature tissue histiocytes, cells of the innate immune system derived from bone marrow monocytes which differentiate into dendritic cells and tissue localized macrophages (Fulmer and Mauldin, 2007; Takahashi and Nakamura, 2013). Tumors can be localized or disseminated with lymph nodes being the most common site of proliferation, followed by organs of the gastrointestinal tract, spleen, soft tissues, and skin (Takahashi and Nakamura, 2013). It is a rare type of cancer in humans and cases have been reported in other species of animals, including chickens, dogs, cats, camels, macaques, and lemurs (Fulmer and Mauldin, 2007; Friederichs and Young, 2008; Soshin et al., 2008; Molenaar et al., 2009; Remick et al., 2009; Takahashi and Nakamura, 2013). Although the cause of HS is
largely unknown, a viral etiology can be postulated as the existence of viruses involved in the development of hematopoietic cancers have been recognized, as in the case of Epstein Barr and human T-lymphotropic virus-induced human lymphomas and similar viruses in non-human primates (Miller et al., 1972; Donahue et al., 1992; Feichtinger et al., 1992; Vereide and Sugden, 2009; Qayyum and Choi, 2014). Additionally it has been proven that the subgroup J avian leukemia virus is associated with the development of histiocytic sarcomatosis in chickens (Pandiri et al., 2009) and an association between persistent Epstein Barr virus infection and human HS has been reported (Kramer et al., 1985). In this study we applied a sequence independent virus discovery technique combined with high throughput sequencing, VIDISCA-454 (De Vries et al., 2011), to investigate the possible involvement of a previously unknown virus in the development of HS in a N. coucang. Several sequences with homology to paroviral genes were identified indicating the presence of a novel parovirus, whose genome was subsequently fully sequenced.

Paroviruses (viral family Paroviridae) are small non-enveloped single stranded DNA viruses which are able to infect a wide range of species of vertebrates (subfamily Parovirinae) and arthropods (subfamily Densovirinae). According to the latest ICTV classification (2013) 8 genera are recognized within the subfamily Parovirinae and 5 of them include viruses infecting primates (Cotmore et al., 2013; Cotmore and Tattersall, 2014). Some paroviruses classified within the genus Dependoparvovirus need the presence of a helper virus for a productive infection while viruses within other genera—the so called autonomous paroviruses—are S phase-dependent: cells must undergo the S phase of growth for viral replication to occur (Berns, 1990).

The spectrum of parovirus induced diseases, which mainly involve young individuals, is very wide and varies from more severe forms [like severe enteritis with high mortality in young dogs (Goddard and Leisewitz, 2010), erythema infectiosum or hydrops fetalis in children both caused by parvovirus B19 (Heegaard and Brown, 2002, p. 19), or the Aleutian disease in minks (Best and Bloom, 2005)] to milder forms [like common respiratory and gastrointestinal diseases in humans (Jarti et al., 2012)]. Finally, parovirus infections can also occur in asymptomatic individuals (Heegaard and Brown, 2002, p. 19; Lau et al., 2008; Clegg et al., 2012). Although there is no formal proof of the existence of oncoviruses within this family, paroviruses have been reported in literature to be associated with both solid and hematopoietic cancers (Fisgin et al., 2002; Li et al., 2012; Schildgen et al., 2013; Ibrahim et al., 2014). However, since they rely on actively replicating cells, the increased presence of these viruses in individuals with cancer might also derive from the permissive nature of the tumor cells and some of these viruses have even proven to possess oncosuppressive effects on transformed cells (Berns, 1990; Nüesch et al., 2012).

Besides reporting the discovery and the molecular characterization of a novel parovirus, the scope of this study was to determine whether a possible correlation existed between this virus and the presence of the histiocytic sarcoma in a N. coucang.

**MATERIALS AND METHODS**

**CLINICAL CASE**

The virus was identified in a 22 year old, male *Nycticebus coucang* (slow loris) named Buddha, held in captivity for 22 years at the Duke University Primate Center and which had no prior significant health issues. The individual was diagnosed with neoplasia and euthanized due to poor condition, although a routine physical inspection 8 months before death revealed an enlarged spleen. A complete postmortem examination was performed.

**CLINICAL SAMPLES**

Representative tissues of Buddha were collected and fixed in 10% neutral formalin. Fixed tissue was processed routinely into paraffin blocks and sections were stained with hematoxylin and eosin and reviewed by a board of certified veterinary pathologist.

Twenty serum samples (belonging to 16 individuals: 11 *N. coucang* and 5 *Nycticebus pygmaeus*) and 61 organs collected at necropsy (belonging to 17 individuals: 11 *N. coucang*—including Buddha—and 6 *N. pygmaeus*) were screened for the presence of the virus. Organ samples included 17 livers, 6 spleens, 15 kidneys, 10 lungs, 6 hearts, 7 intestines (5 small intestines and 2 large intestines). Altogether these samples belonged to 25 individuals (18 *N. coucang* and 7 *N. pygmaeus*) with various types of disease. Liver, spleen, kidney, lung, and intestine samples from Buddha were available as well as serum or whole blood collected on 4 different time points: year 2000 (serum), year 2005 (serum), year 2007 (whole blood), and year 2008 (serum).

Serum samples and organs were stored at −80°C until virological examinations were performed.

Housing management and sample collection from the animals in this report were approved by the appropriate federal and institutional regulatory authorities.

**VIRUS DISCOVERY**

Sequence independent virus discovery was performed on a serum sample collected from Buddha at necropsy (2008) with the previously described VIDISCA-454 procedure (De Vries et al., 2011) with minor modifications. After a centrifugation and DNase treatment to remove both intact cells and host DNA derived from broken cells, viral nucleic acids were isolated from 100 μl of serum with the QIAmp DNA mini kit (Qiagen). Subsequent to the ligation of adaptors containing specific Roche-454 primer binding sequences, an ampiclon size-selection was performed to prevent the amplification of DNA fragments smaller than 200 bp using Agencourt AMPure XP beads (Beckman Coulter), followed by 30 cycles of PCR amplification. The amplified library was subjected to 2 consecutive purification rounds with Agencourt AMPure XP beads to completely remove excess primers and short fragments and DNA concentration was measured on a Qubit Fluorometer (Quant-it ds DNA HS kit, Invitrogen). The library was pooled with other samples, the average size of the whole library was estimated with Agilent 2100Bioanalyzer (high sensitivity DNA kit, Agilent Technologies) and the final concentration (copies/μl) was calculated using the KAPA Library Quantification kit (KAPA Biosystems). Samples were then diluted to a final concentration of 1 million copies/μl and used as input for the emulsion PCR (LIB-A emPCR kit, Roche) and 454 pyrosequencing (Roche).
After sequencing, primer sequences were trimmed from every read and sequences were assembled with CodonCode Aligner software, version 3.5.6. The contigs (consensus sequences derived from reads found multiple times) and unassembled sequences were compared to known nucleotide and protein sequences in the GenBank database using different standalone BLAST tools (blastn and tblastx) (Altschul et al., 1990). Blast results were visualized using the MEGAN software version 4.70.4 (Huson et al., 2011).

FULL GENOME SEQUENCING
Specific primers were designed on the viral sequences identified with VIDISCA-454 and PCRs using DreamTaq DNA polymerase (Thermo Scientific) were performed to connect fragments. Sequencing reactions were carried out with nested primers directly on the amplified products using the Big Dye terminator chemistry (BigDye® Terminator v1.1 Cycle Sequencing Kit, Applied Biosystems).

The ends of the genome were determined using genomic fragments obtained by specific digestion with 2 different restriction enzymes (MseI and CviAII from New England Biolabs) to obtain overlapping fragments, to which VIDISCA adaptors were subsequently ligated; semi specific PCRs were then performed with a combination of one primer annealing to the known viral sequence and one to the adaptor. After sequencing the obtained amplicons, the novel sequence was used as a template for new primer design and the whole procedure was repeated until reaching the end of the genome. Specific PCRs were used as confirmation. All primers used for PCR and sequencing reactions are available upon request.

VIRTUAL SCREENING AND DNA QUANTIFICATION
DNA isolations were performed from 100 μl of serum with the QIAamp DNA mini kit (Qiagen) and from 40 μl of blood or about 20 mg of tissue (about 5 mg for spleen) with the DNEasy Blood and Tissue kit (Qiagen). Absolute quantification of viral DNA (copies/ml of serum or blood and copies/g of tissue) was achieved using plasmid-based standards: a portion of the NS1 ORF (position in the complete genome: nt 1129–1527) was amplified and cloned into TOPO® cloning vector according to the instructions of the manufacturer (TOPO® TA cloning, Invitrogen), followed by plasmid purification (Plasmid DNA purification Nucleobond Xtra Midi, Macherey-Nagel) and quantification (NanoDrop 2000c, Thermo Scientific). Quantitative Real Time PCR assays were performed with IQ Supermix (BioRad) and using 4 μl of DNA as input, with the following primers and probe: *Buddha_RT_F*, GCTAATCTGGTGGGAAGAGG; *Buddha_RT_R*, CCTTTGGCATCTACCTGCAG; *Buddha_RT_P*, 5′FAM—CCGCCCAAGGAGACCTTACG— TAMRA 3′. Real-time PCR reactions were performed with the Light Cycler 480 system (Roche).

To detect possible differences between sequences obtained from various organs or different years, all positive samples were subjected to a specific amplification of a 1231 nt long portion of the VP1 gene using DreamTaq DNA polymerase (Thermo Scientific) with primers *Buddha_VP_5F*-ATGTCTCCACTTATTCTTG— and *Buddha_14_R*-ACGATCTGGGTATGACTTTC. Amplicons were diluted 1:10 and directly sequenced employing the Big Dye terminator chemistry (BigDye® Terminator v1.1 Cycle Sequencing Kit, Applied Biosystems).

IDENTIFICATION OF INTEGRATED OR EPISOMAL VIRAL DNA
To detect the presence of latent viral forms (extra-chromosomal circular episomal DNA or integrated DNA) in the different tissues, specific PCR-based assays were designed. A graphical overview of the methods used to detect latency is available in Figure 1. For this purpose the DNA isolated from all organs collected during the necropsy of *Buddha* (lung, liver, spleen, kidney, small, and large intestine) and from blood (collected one year before the animal died) were used as input.

To detect the presence of circulated viral genome an inverted nested PCR was performed using primers annealing at the end of the two open reading frames (ORFs) (Figure 1A): *I_Buddha_R1*-CCTTTGTCGATCTGTCCTCCAAATAATTGC— and *I_Buddha_F1*-CCAGTGAGGGAGATGACTCATCACC— for the first step of amplification; *I_Buddha_R2*-GTAATGCTTTAGATCCAG— and *I_Buddha_F2*-TGGAGTGAGTAAATACCGACATG—for the nested amplification. As a control DNA isolated from serum samples (collected in 2008 both with and without VIDISCA pre-treatment) was also included.

To detect chromosome-integrated viral forms 3 different approaches have been employed, of which 2 involved a specific enzymatic digestion of the isolated DNA (Figure 1B): 7.5 μl DNA eluate was cut (restriction site at nucleotides 868–873) in a 20 μl reaction mix containing 5 U of NdeI restriction enzyme (New England Biolabs) during an incubation of 2 h at 37°C. Prior to inactivation, 5 μl of cut DNA were collected and used to perform a specific ligation of VIDISCA adaptors (De Vries et al., 2011) to the digested fragments using 4 U of T4 DNA ligase (life technologies). Afterwards 2 semi virus-specific nested amplifications were performed using one primer complementary to the virus (*I_Buddha_R1* and *I_Buddha_R2* for the 5′ side; *I_Buddha_F1* and *I_Buddha_F2* for the 3′ side) and one adaptor specific primer. In parallel, 5 μl of the cut DNA was subjected to an inactivation step for 20 min at 65°C, followed by an overnight incubation at room temperature with 4 U of T4 DNA ligase to allow self-ligation and consequent circularization of the digested fragments (containing host sequences flanking the viral integrated DNA). Two specific inverted nested PCRs were used afterwards with primer pairs *I_Buddha_F1/I_Buddha_R3* (TCCCGA CACAAATTACGGAACAC) and *I_Buddha_R1/I_Buddha_F3* (GACGTGCTTTTGGATGACTGTTCG) during the first step and *I_Buddha_F2/I_Buddha_R4* (AAAAATTGATTTTCCAT TTAGGTTAGTC) and *I_Buddha_R2/I_Buddha_F4* (CAAACT CTGCAATGGTGTGTAGATG) during the second amplification step.

The third approach for integrated DNA detection made use of the Alu elements, DNA sequences which are highly repeated in primate genomes (Häsler and Strub, 2006). A primer (Ny_Alu: CCTCCCAAGAGTGGTGGAGATGAC) binding to one of these regions was designed (according to GenBank sequence with accession number DQ822059) and used alone (as a negative control) or in combination with viral specific primers (*I_Buddha_R1* or *I_Buddha_F1* for the first amplification step and *I_Buddha_R2*...
Canuti et al. Novel slow loris parvovirus

FIGURE 1 | Graphical overview of the methods used to detect latent viral forms. (A) Method used to detect episomal genomic DNA. On the top the genome organization of the Sl.L-PV-1, on the bottom a representation of the predicted circular form. Red arrows represent primer binding sites. The use of reverse primer annealing at the beginning of NS1 and forward primers annealing at the end of VP1 allows the amplification the connecting genomic sequence. (B) Restriction enzyme based methods to detect integrated virus. The purple lines represent the host genomic sequence, the orange flashes indicate restriction enzyme sites and the orange boxed indicate artificially ligated adaptors. (B1) It is shown how, after overnight ligation of the digested DNA, the obtained fragment would self-ligate in a circular form and how a specific amplification would allow to amplify the integration site. (B2) It is shown how, after the ligation of specific adaptors to the obtained digested fragments, a semi specific PCR would allow the amplification of the integration site. (C) Method to detect the integrated virus based on repeated Alu sequences in the host genome. Purple boxes represent Alu sequences and red arrows represent primer binding sites. A comparison of the PCR results obtained amplifying the template with either a mixture of Alu binding primers and specific primers or Alu binding primers alone (negative control) would allow to amplify the integration site and determine which amplified fragment on gel corresponds to it.

or I_Buddha_F2 for the nested amplification) to amplify the putative integration region (Figure 1C).

All amplifications were performed by using 5 μl of DNA as input in a 50 μl PCR mix containing DreamTaq DNA polymerase (Thermo Scientific) and 0.2 μM primers: PCRs were performed according to the following thermo profile: initial denaturation at 95°C for 5 min, followed by 35 cycles (25 during the nested PCR) at 95°C for 30 s, 60°C for 30 s and 72°C for 1.5 min (for the episomal DNA test) or 3 min (for the integration tests) and a final elongation cycle at 72°C for 7 min. Positive PCR products were cloned into the TOPO® cloning vector (TOPO® TA cloning, Invitrogen) and sequenced employing Big Dye terminator chemistry (BigDye® Terminator v1.1 Cycle Sequencing Kit, Applied Biosystems) using betaine at a final concentration of 1 M to resolve secondary structures in the DNA.

SEQUENCE AND PHYLOGENETIC ANALYSIS

To characterize the phylogenetic placement of the novel virus, 38 NS1 amino acid sequences of known parvoviruses were downloaded from the GenBank database and aligned together with the one predicted in this study from the obtained nucleotide sequence using the Cobalt Multiple Alignment Tool (http://www.ncbi.nlm.nih.gov/tools/cobalt/). Only complete sequences were included in the analysis. Alignments were manually edited when needed with BioEdit software version 7.0.9.0 (Hall, 1999). DNA secondary structure predictions were obtained using the mfold web server (http://mfold.rna.albany.edu/?q=mfold/download-mfold).

ACCESSION NUMBERS

The genomic sequence obtained in this study has been deposited in the GenBank database under the accession number KP120516.

RESULTS

We examine here the case of Buddha, a male slow loris, who was euthanized at the age of 22 years because of diffuse HS. A serum sample collected at necropsy was used as input for virus discovery in search for a novel virus that could explain the disease.

PATHOLOGICAL DETAILS

During the postmortem examination the principal observations included a significantly enlarged spleen with a homogeneous
cut surface and a mottled liver with irregular patches of pallor. Pancreatic and mediastinal lymph nodes were enlarged.

Incidental lesions included a cystic mass in the right mammary gland and several small ulcers in the fundus of the stomach. Histologic examination of the spleen revealed a loss of normal architecture and an intense infiltration of neoplastic round to polygonal cells with moderate variation in cell and nuclear sizes (anisocytosis and anisokaryosis). Mitotic figures were common and multinucleate cells were occasionally seen. In the liver there were similar neoplastic cell aggregates surrounding the portal veins and the central veins, expanding the associated connective tissue. Ingested red blood cells (erythropagocytosis) by neoplastic cells were also observed. Affected lymph nodes were characterized by a loss of normal architecture which was replaced by sheets of round to polygonal neoplastic cells similar to those found in the liver and spleen. These findings led to a diagnosis of disseminated histiocytic sarcoma.

Additional findings included evidence of an apocrine gland cyst causing the mass in the right mammary gland. In addition there was evidence of inflammation and necrosis in the adrenal glands associated with a protozoal infection, interpreted to be Toxoplasma gondii. In addition, large deep basophilic intranuclear clear inclusions were found in a minority of adrenal cortical cells. Renal tubules contained eosinophilic droplets in the epithelial cells, as is often seen in mice with histiocytic sarcoma, although the cause is not known. Chronic interstitial nephritis was also evident.

**IDENTIFICATION OF A NOVEL PARVOVIRUS AND COMPLETE GENOME SEQUENCING**

To explore the possibility of viral involvement in the etiopathogenesis of the HS we used VIDISCA-454, a sequence independent virus identification technique which is able to detect virtually any DNA and RNA virus from various clinical samples (van der Hoek et al., 2004; Canuti et al., 2011; Jazaeri Farsani et al., 2013; Tan et al., 2013; Canuti et al., 2014; Oude Munnink et al., 2014; Pariani et al., 2014). A total of 8003 sequence reads were obtained from the serum sample of the slow loris with HS and, among these, 5 sequences were identified with homology to different members of the Parovirinae subfamily: 3 were identified with blastn (nucleotide identity: 62–70%) and 2 were only recognizable when identity search was performed at amino acid level (amino acid identity: 69–82%). Those recognized as viral fragments were used as template for primer design, and a combination of specific PCRs and genome walking techniques allowed retrieval of the almost complete genomic sequence of the virus (only part of the terminal repeats is lacking), which was tentatively named Slow Loris parvovirus 1 (SL-L-PV-1). The genomic sequence allowed us to identify 3 further viral sequences which were not identifiable via identity search. In total 35 reads (0.44% of the total) belonged to the novel virus.

**GENOME ORGANIZATION**

The rules set by the parvovirus study group in the latest ICTV report mention that a novel parvovirus, which lacked isolation, can be classified within the Paroviridae family only if the complete coding sequence is provided and the typical paroviral motif patterns can be recognized (Cotmore et al., 2013).

The genome of the novel parvovirus is 4844 nt and the genomic organization reflects the other members of the Parovirinae subfamily with 2 large ORFs and terminal sequences which form end loop structures important for viral replication, although the structure of the loops could not be entirely resolved since only partial sequences could be retrieved (Figure 2) (Berns, 1990). The first ORF—located at the 5' part of the genome (nt 146–1894)—putatively encodes for the non-structural protein NS1 (582 AA). The second ORF—located at the 3' part (nt 2187–4655)—encodes for the capsid protein VP1 (822 AA).

Other molecular features typical of paroviruses were also identified (Figure 2). A phospholipase A2 domain of SL-L-PV-1, that is conserved in the majority of paroviruses and which is essential for viral genome transfer to the nucleus, is located at the N-terminal part of the VP1 unique region and contains the typical PLA2 catalytic domain (HDXXY, AA 140–144) and Ca++ binding loop (YXGXG, AA 117–121) (Zádori et al., 2001).

Another molecular marker of paroviruses is the presence of conserved helicase sequence motifs in the NS1 protein (Walker et al., 1997; Lou et al., 2012). Within the carboxy-terminal half of the NS1 protein of SL-L-PV-1 (AA 336–423) the typical ATP binding loop or p-loop (Walker box A: GXXXGXG(T/S)) could be identified, immediately followed by the Mg++ binding Walker B (hhhD/E/E) and B’ motifs. Finally, the C motif (a stretch of hydrophobic residues usually followed by asparagine), common to the helicases belonging to the superfamilly type III, was also present (Figure 2).

We were able to obtain only part of the sequences from the terminal non coding regions, 148 and 192 nt of the 5’ and 3’ end respectively. An alignment of these 2 sequences shows that they are 100% identical (but oriented in the opposite direction) and start differentiating from the ATG start codon of NS1, which becomes ACG on the 3’ side terminal sequence (Figure 3). These data suggest that SL-L-PV-1 possesses identical inverted terminal repeats. Besides, a 44 nt sequence was identified which is present only on the 3’ side of the genome, just after the TAA stop codon of VP1/VP2, that contains a 21 nt region that can fold into a small hairpin (Figures 2, 3).

**PHYLOGENETIC ANALYSIS AND PROPOSED CLASSIFICATION**

Phylogenetic analysis of SL-L-PV-1 was performed using the predicted amino acid sequences of the NS1 protein belonging to members of the Parovirinae subfamily (Figure 4). In the phylogenetic tree the 8 Parovirinae genera are indicated: each defined cluster was supported by a significant bootstrap value (between 93 and 100). Only 2 viruses did not cluster in any of these 8 clades: a parvovirus identified in Artibeus jamaicensis fruit bat (Aj-Bt-PV-1, which we previously reported as the first member of a novel parvovirus genus, Canuti et al., 2011) and the SL-L-PV-1. Both viruses are located between the Dependoparvovirus and the Tetraparvovirus genera and do not significantly cluster with any other known parvovirus, possibly representing 2 independent still undefined genera.

To better clarify the relationship between SL-L-PV-1 and the most closely related paroviruses, the amino acid identities of
FIGURE 2 | Genome organization of the slow loris parvovirus 1 (SLL-PV-1). Schematic representation of the genome organization of SLL-PV-1 with the two main ORF (NS1 and VP1) indicated with the respective predicted protein size. On the top the helicase domain of SLL-PV-1 (AA 336–423) is compared with the one of other members of the Parvovirinae sub-family. The conserved Walker motifs (A,B,B',C) are indicated in boxes (Walker et al., 1997; Lou et al., 2012). For sequences accession numbers see Figure 3. The phospholipase A2 domain comparison between SLL-PV-1 (AA 109–167) and other members of the Parvovirinae sub-family is presented at the bottom. The conserved Calcium binding domain (1) and enzymatic core (2) motifs are indicated by boxes (Zádori et al., 2001). Finally, the hypothetical 5' and 3' specific terminal hairpins are represented by dashed lines and on the right a small hairpin identified only on the 3'end of the genome is shown just after the underlined VP1 stop codon. The mfold web server (http://mfold.rna.albany.edu/?q=mfold/download-mfold) was used to predict the secondary structure.

both NS1 and VP1 proteins within and between the clades were calculated (Table 1). Considering NS1 protein, the virus with the highest identity to SLL-PV-1 was the Bovine adeno-associated virus (BAAV, 29.1%), followed by other members of the Dependoparvovirus genus, which, on average, was the clade closest to SLL-PV-1. The Tetraparvovirus clade and Aj-Bt-PV-1 are approximately equidistant from SLL-PV-1. The same trend could be noted for Aj-Bt-PV-1.

The classification rules for parvoviruses state that a genus is defined as a monophyletic group in which the NS1 amino acid sequences of all included viruses are generally more than 30% identical to each other and less than 30% identical to those of other genera (Cotmore et al., 2013). According to our analysis, both Aj-Bt-PV-1 and SLL-PV-1 could be considered the first members of 2 novel genera: their NS1 amino acid sequences are less than 30% identical to the ones of the viruses in the closest genera (Table 1), less than 25 and 27% respectively, and they are not part of a bootstrap supported monophyletic group (Figure 4).

SCREENING AND VIRUS QUANTIFICATION
Twenty serum and 61 organ samples altogether belonging to 25 individuals (18 N. coucang and 7 N. pygmaeus) were screened for the presence of SLL-PV-1, but only samples collected from the animal in which the virus was originally identified were positive. All organs collected during necropsy were positive for the
virus, with high viral loads as shown in Table 2. Liver, spleen, and kidneys were the organs where the virus reached the highest loads.

Surprisingly, all blood/serum samples collected at different time points were PCR positive. Those samples were collected from Buddha on a time frame of 8 years (from the year 2000 until 2008) and the virus was constantly found at moderately high concentrations, with the highest titre found in whole blood (5.39E + 08 DNA copies/ml) 7 months prior to the death of the animal (Table 2).

VIRUS EVOLUTION

A 1231 nt fragment of the VP1 ORF end was sequenced from all positive samples in order to detect variation between different body sites or among the 8 years of infection: 16 polymorphic sites were noted (Table 3). The polymorphisms predominantly included transitions (81.25%, 13/16) and only two were non-synonymous. If we consider only the sequences obtained from serum there is an accumulation of 5 substitutions (all transitions located between codons 405 and 536) during the years, one of which leads to an amino acid change. However, no fixation can be accounted if we consider altogether the sequences from 2008 (those retrieved both from serum and from all the organs).

The appearance of new variable sites over time can also be noted, like at codon position 645 where a polymorphism appeared only in 2008. Interesting to notice is that kidneys and, most of all, the intestine are the locations where most polymorphisms characterizing earlier time points were conserved (positions 742, 763, and 777).

LATENT VIRUS DETECTION

Since the virus was detected in samples collected from Buddha during 8 years the presence of integrated or episomal viral genomes could be postulated. Besides, the disruption of an oncolytic gene caused by viral integration could have been at the origin of the HS and therefore the presence of integrated viral genomes in all tissues (including whole blood) was investigated by means of three different methods - since the integration location could not be predicted (Figure 1). No evidence for integrated viruses could be found. In addition, there was also no evidence of a circular covalently closed genomic form which could have persisted in tissues as an episomal form.

DISCUSSION

Cancer is one of the leading cause of human death worldwide and it represents a considerable health concern for domestic and wild animals as well as animals kept in captivity (WHO|Cancer1; Misdorp, 1996; Kelsey et al., 1998; McAloose and Newton, 2009; Remick et al., 2009). Although the full process of tumorigenesis is not completely understood, it is known that accumulation of mutations in proto-oncogenes (such as those involved in the regulation or suppression of cell replication or tumors) or the effect of viral infections are involved in the progression (Bergers and Benjamin, 2003; McAloose and Newton, 2009). The number of recognized oncogenic viruses is increasing and nowadays several examples—both from the human and animal fields—are well characterized. The best known examples are the papillomaviruses causing cervical cancers in humans and different types of genital and cutaneous cancers in aquatic mammals, the hepadnaviruses causing hepatitis in humans and woodchucks, the Epstein Barr virus which is responsible for Burkitt’s lymphoma or retroviruses which are at the origin of different types of malignancies in humans and other mammals (McAloose and Newton, 2009; Braoudaki and Tzortzatou-Stathopoulou, 2011; Butt and Miggin, 2012; Pannone et al., 2014). It is therefore very important to identify novel oncoviruses and extensively study them in order to understand their tumorigenic mechanisms, especially in light of future developments such as prevention strategies.

In this study we investigated a case of diffuse histiocytic sarcoma—a rare but very aggressive type of hematopoietic tumor which can develop in different animal species (Fulmer and Mauldin, 2007; Friedrichs and Young, 2008; Soshin et al., 2008; Molenaar et al., 2009; Remick et al., 2009; Takahashi and Nakamura, 2013). To investigate the possible viral involvement in the etiopathogenesis of the HS a broad spectrum virus discovery technique was employed, which is able to detect virtually any DNA or RNA viruses present in a clinical sample (De Vries et al., 2011, 2012; Oude Munnink et al., 2014). A novel parvovirus was identified and molecularly fully characterized. The virus, which we named Slow Loris parvovirus 1 (S.L.-PV-1), is around 5 kb

1http://www.who.int/mediacentre/factsheets/fs297/en/ [Accessed May 19, 2014].

![Alignment of the available inverted terminal repeat sequences of Slow loris parvovirus 1 (S.L.-PV-1). The 5' side ITR is oriented 5' to 3', while the 3' side ITR is oriented in the opposite direction.](image-url)
FIGURE 4 | Phylogenetic analyses of slow loris parvovirus 1 (SL.L-PV-1).

The evolutionary history of SL.L-PV-1 and the other members of the Parvovirinae subfamily was inferred using the Maximum Likelihood method (Felsenstein, 1981) based on the rREV + Freq model (Dimmic et al., 2002), identified as the best fitting model after the model test analysis, using MEGA6 (Tamura et al., 2013). A distance Gamma distribution was used to model evolutionary rate differences among sites (+G, parameter = 2.5202). The rate variation model allowed for some sites to be evolutionarily invariable (+I, 4.0614% sites). All positions with less than 95% site coverage were eliminated. The outcome of the bootstrap analysis (Felsenstein, 1985) is shown next to the branches. The genera are designated by square brackets and the accession numbers of the reference strains are indicated next to the strain name. The virus described in this study is indicated in bold.
et al., 1985; Canuti et al., 2011), and liver, spleen and kidneys were the organs where the virus reached the highest loads. The positive, as also reported for other parvoviruses (Meunier

Table 1 | Identities between and within the clades more closely related to Sl.L-PV-1.

|          | Dependoparvovirus | Tetraparvovirus | Aj-Bt_PV-1 | Sl.L-PV-1 |
|----------|-------------------|-----------------|------------|-----------|
| Dependoparvovirus | 81.87 (61–45) | 17.21 (18.9–15.1) | 21.01 (22.4–19.4) | 23.4 (24.1–22.4) |
|          | 43.27 (64.3–28) |                 |            |           |
| Tetraparvovirus | 21.18 (23.4–18.6) | 50.14 (72.9–273) | 18.8 (19.6–18.2) | 20.4 (20.9–19.6) |
|          | 46.45 (75.7–29.6) |                 |            |           |
| Aj-Bt_PV-1 | 24.81 (26–22.4) | 22.6 (23.1–22) | id         | 21.3      |
| Sl.L-PV-1 | 26.6 (29.1–24.5) | 22.8 (25–19.9) | 23.6       | id        |

Values represent average percentage identity (upper limit—lower limit) calculated using representative members of each species in the clades. Values in bold (bottom left) refers to NS1 amino acid sequence, while the other numbers (top right) refer to VP1 amino acid sequence. On the diagonal in italic are the identities within each clade; id, identical. The extended analysis is available in the Supplementary Tables 1, 2.

Table 2 | Sl.L-PV-1 loads determined in different organs (collected at necropsy in 2008) and from serum/blood samples collected during various years.

| Material          | Collection date (mm/dd/yyyy) | Viral load (copies/g or copies/ml) |
|-------------------|-----------------------------|-----------------------------------|
| Lung              | 06/03/2008                  | 6.09E + 07                        |
| Small intestine   | 06/03/2008                  | 4.82E + 07                        |
| Large intestine   | 06/03/2008                  | 1.24E + 07                        |
| Liver             | 06/03/2008                  | 1.87E + 08                        |
| Spleen            | 06/03/2008                  | 1.79E + 08                        |
| Kidney            | 06/03/2008                  | 1.43E + 09                        |
| Serum             | 03/21/2000                  | 1.90E + 07                        |
| Serum             | 12/08/2005                  | 4.20E + 07                        |
| Whole blood       | 11/08/2007                  | 5.39E + 08                        |
| Serum*            | 06/03/2008                  | 1.08E + 06                        |

*After VIDISCA pre-treatment (centrifugation and DNase treatment prior to DNA isolation)

in size and possesses all the molecular features typical of parvoviruses, including sequences coding for conserved enzymatic motifs and the 2 main ORFs, flanked by non-coding terminal regions, which appear identical but inverted like described for other parvoviruses (Lusby et al., 1980; Berns, 1990; Deiss et al., 1990). The virus is phylogenetically located between the Dependoparvovirus and the Tetraparvovirus genera and, according to the classification rules defined by the ICTV (Cotmore et al., 2013), is possibly the first member of a new genus.

Thanks to the availability of a series of serum and organ samples collected over multiple years from slow loris with various diseases, we were able to screen different samples from a total of 25 individuals belonging to the N. coucang species and to the closest related species N. pygmaeus. No other animal was positive for the virus but, as expected, all organs collected during the necropsy were positive, as also reported for other parvoviruses (Meunier et al., 1985; Canuti et al., 2011), and liver, spleen and kidneys were the organs where the virus reached the highest loads. The high viral concentrations found in these organs might reflect their elevated content of blood and blood cells. Besides, during the histological investigation the presence of basophilic inclusions in the renal tissue could be observed and these might represent parvoviral accumulations, similar to other reports for parvoviruses both in vivo (Hayes et al., 1979; Bestetti and Zwahlen, 1985; Porter et al., 1988; Decaro and Buonavoglia, 2012) and in vitro (Inaba et al., 1973; Oleksiewicz et al., 1996). Surprisingly, all blood or serum samples collected during various years were positive at a rather constant load: we could detect viremia 8 years prior to the death of the animal. Given the involvement in the disease of white blood cells, a presumed condition of immunosuppression (caused either by the virus, the tumor, or by a combination of these 2 factors) can be postulated and might be a possible explanation for the fact that the virus was not cleared in 8 years. The supposed presence of immunodeficiency in the loris is supported by the detection of opportunistic infections, as the pathological tests reported the presence of Toxoplasma gondii infection.

Since HS is a fast and very aggressive type of cancer we could have hypothesized that the virus was present in the Loris before tumor development. Histiocytes can refer to cells of either the macrophage or dendritic cell lineage as both arise from a common precursor cell. Neoplasms of histiocytes can arise from macrophages or one of two types of dendritic cells, Langerhans cells or interstitial dendritic cells. Langerhans cells are found within the epithelium and interstitial dendritic cells occupy a perivascular position in most tissues. Most forms of HS in animals arise as a malignant proliferation of interstitial dendritic cells, although there is one form, the hemophagocytic variant, that arises from macrophages (Fulmer and Mauldin, 2007; Takahashi and Nakamura, 2013; Moore, 2014). There is no established classification scheme for HS in prosimians. We interpreted this tumor to have most likely arisen from interstitial dendritic cells. Some parvoviruses have proven tropism for cells of the hematopoietic system and the bone marrow providing the perfect condition for parvoviral replication, since a wide spectrum of cells at different dividing stages are present and parvoviruses need actively dividing cells (S phase) to replicate (Berns, 1990; Segovia et al., 1991). In fact, hematopoietic...
Table 3 | Nucleotide polymorphisms in Sl.L-PV-1 identified over time and in different organs.

| nt          | 3399 | 3443 | 3506 | 3530 | 3722 | 3746 | 3794 | 3923 |
|-------------|------|------|------|------|------|------|------|------|
| AA          | 405 (V) | 419 (L) | 440 (Y) | 448 (E) | 512 (P) | 520 (Q) | 536 (E) | 579 (T) |
| Serum 2000  | A (I) | T | T | G | T | A | A | Y |
| Serum 2005  | R (V/I) | Y | Y | R | Y | R | R | Y |
| Whole blood | R (V/I) | Y | Y | R | Y | R | R | Y |
| Serum 2008  | G | C | C | G | C | R | G | C |
| Small intestine | R (V/I) | Y | Y | G | Y | A | R | C |
| Large intestine | G | Y | Y | G | Y | G | R | C |
| Lung       | G | C | C | G | C | A | G | C |
| Spleen     | G | C | C | G | Y | A | G | C |
| Liver      | G | C | C | G | Y | A | G | C |
| Kidneys    | R (V/I) | Y | Y | R | Y | R | R | Y |

| nt          | 3992 | 4040 | 4121 | 4331 | 4412 | 4475 | 4517 | 4558 |
|-------------|------|------|------|------|------|------|------|------|
| AA          | 603 (S) | 618 (R) | 645 (F) | 715 (G) | 742 (S) | 763 (T) | 777 (V) | 791 (S) |
| Serum 2000  | Y | R | T | T | R | M | Y | G |
| Serum 2005  | Y | R | T | K | A | C | Y | K (S/I) |
| Whole blood | Y | R | T | K | A | C | C | K (S/I) |
| Serum 2008  | C | R | Y | K | A | C | C | K (S/I) |
| Small intestine | C | R | Y | K | R | M | Y | K (S/I) |
| Large intestine | Y | R | Y | K | A | C | C | K (I/S) |
| Lung       | C | A | Y | K | A | C | C | K (I/S) |
| Spleen     | Y | R | Y | K | A | C | C | K (I/S) |
| Liver      | C | A | Y | K | A | C | C | K (I/S) |
| Kidneys    | Y | A | Y | K | A | C | C | K (I/S) |

Nucleotide positions refer to the whole genome as reported in GenBank (AN: KP120516); amino acids positions refer to the VP1 ORF. Where the mutation caused an amino acid change the new amino acid is indicated. Polymorphisms are indicated: Y (C or T), R (A or G), K (T or G), M (C or A).

Disorders, like leucopenia or alterations in the bone marrow, can be observed in infected individuals (Larsen et al., 1976; Boosinger et al., 1982).

Although there is no formal proof of the existence of onco-paroviruses, a causative link between the novel parvovirus and the HS could not be ruled out and therefore we investigated this hypothesis by exploring the eventual presence of latent forms of the virus. It is known that parvoviruses can establish latency by integrating in their hosts' genome (Schnepp et al., 2005; Kapoor et al., 2010), and an integration event might cause the disruption of important onco-suppressors and be one of the initial causes for tumor development. Episomal DNA forms of various parvoviruses have recently been detected (Kapoor et al., 2011; Zhao et al., 2012) and parvoviral DNA was found to persist in different tissues (Schneider et al., 2008; Norja et al., 2012), sometimes even in correlation with tumors (Li et al., 2012; Schildgen et al., 2013), although without a causative link. Since it was impossible to predict in which way the virus would have persisted, this hypothesis was tested with 4 different methods aiming at identifying either potentially integrated viral DNA or circular covalently closed genome persisting in tissues as episomal forms. None of these approaches gave evidence for latent forms of the virus in any of the tested organs (including whole blood).

A mutation hotspot located on the end side of the VP1 ORF was identified and an increase in variation during the years was observed. The evolutionary rates estimated in literature for parvoviruses are around 10E-4 substitutions per site per year in the studied genomic region (Shackelton and Holmes, 2006; Zehender et al., 2010; Streck et al., 2011) and the amount of substitutions we observed reflect those rates. However, these previously published rates have been estimated at an animal population level and not inter-host. In addition, fixation rates are connected to the transmission route of the virus: the sequences of the viral subpopulation which are transmitted to other individuals depend on the viral variation at the body site where the virus is shed. Since no other infected individual has been identified no postulations could be made on the transmission route of the virus and also no evolutionary rate estimations were possible. Nevertheless, the observed increase in sequence variation over time is inconsistent with a latency hypothesis: an integrated virus would evolve at the same evolutionary rate as its host and therefore, in case of integration, no variation would be observed.

It is reasonable to believe that the Sl.L-PV-1 was not the cause of the malignancy but merely found the ideal replication condition in cancer cells since, as discussed above, it is well known that parvoviruses need actively replicating cells (S-phase) in order to...
proliferate (Berns, 1990). In fact it is known that certain viruses, called oncolytic viruses, have tropism for specific cancer cells and they can even lead to "spontaneous regression" of malignancies (Butt and Miggin, 2012; Sze et al., 2013). This has been proven for the adenov-associated dependoparvovirus, although in an indirect way by enhancing adenoviral replication, and for a rodent parvovirus (Nüesch et al., 2012; Laborda et al., 2013). Future research will have to clarify whether this viral infection precedes tumor development and has a role in the oncogenic process, whether the virus simply benefits from the replication activity of the cancer cells or if the persistent viremia has no correlation with the HS. An answer to this question will be obtained by identifying the cell types where viral replication occurs after the detection of other infected loris and the constant monitoring of their physical condition and disease progression, and after the discovery of related viruses in other animals with similar malignancies. Although more studies are required to provide a conclusive answer, the infection with SL-L-PV-1 might have delayed tumor progression.

virus simply benefits from the replication activity of the cancer cells or if the persistent viremia has no correlation with the HS. An answer to this question will be obtained by identifying the cell types where viral replication occurs after the detection of other infected loris and the constant monitoring of their physical condition and disease progression, and after the discovery of related viruses in other animals with similar malignancies. Although more studies are required to provide a conclusive answer, the infection with SL-L-PV-1 might have delayed tumor progression.

In conclusion we discovered and molecularly characterized a novel parvovirus, the first member of a not yet defined genus and the first described in prosimians. The virus was identified in a slow loris with HS but we found no evidence for a causative involvement in the neoplastic disease and postulated that the virus had a replication advantage derived from the constantly replicating cancer cells.

ACKNOWLEDGMENTS

The authors thank Dr. Rienk Jeeninga for appreciated advices on designing latency tests and Dr. Elena Herrera Carrillo for providing the protocol for sequencing the terminal loop regions. This study was supported by funding from the European Community’s Seventh Framework Programme (FP7/2007–2013) under the project EMPERIE, EC grant agreement number 223498.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: http://www.frontiersin.org/journal/10.3389/fmicb.2014.00655/abstract

REFERENCES

Altschul, S. F., Gish, W., Miller, W., Myers, E. W., and Lipman, D. J. (1990). Basic local alignment search tool. J. Mol. Biol. 215, 403–410. doi: 10.1016/S0022-2836(85)80360-2
Bergers, G., and Benjamin, L. E. (2003). Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3, 401–410. doi: 10.1038/nrc1093
Berens, K. L. (1990). Parvovirus replication. Microbiol. Rev. 54, 316–329.
Best, S. M., and Bloom, M. E. (2005). Pathogenesis of aleutian mink disease parvovirus and similarities to b19 infection. J. Vet. Med. B Infect. Dis. Vet. Public Health 52, 331–334. doi: 10.1111/j.1439-0405.2005.00864.x
Bestetti, G., and Zwahlen, R. (1985). Generalized parvovirus infection with inclusion-body myositis in two kittens. J. Comp. Pathol. 95, 399–397. doi: 10.1016/0021-9975(85)90043-X
Boosinger, T. R., Rebar, A. H., DeNicola, D. B., and Boon, G. D. (1982). Bone marrow alterations associated with caninle parvoviral enteritis. Vet. Pathol. 19, 558–561.
Braoudaki, M., and Tzortzatou-Stathopoulou, F. (2011). Tumorigenesis related to retroviral infections. J. Infect. Dev. Ctries. 5, 751–758. doi: 10.3855/jidc.1773
Butt, A. Q., and Miggin, S. M. (2012). Cancer and viruses: a double-edged sword. Proteomics 12, 2127–2138. doi: 10.1002/pmic.201100526
Canuti, M., Deijis, M., Jazaeri Farsani, S. M., Holwerda, M., Jubbink, M. F., de Vries, M., et al. (2014). Metagenomic analysis of a sample from a patient with respiratory tract infection reveals the presence of a γ-papillomavirus. Front. Microbiol 5:347. doi: 10.3389/fmicb.2014.00347
Canuti, M., Eis-Huebinger, A. M., Deijis, M., de Vries, M., Drexler, J. F., Oppong, S. K., et al. (2011). Two novel parvoviruses in frugivorous new and old world bats. PLoS ONE 6:e29140. doi: 10.1371/journal.pone.0029140
Clegg, S. R., Coyne, K. P., Dawson, S., Spibey, N., Gaskell, R. M., and Radford, A. D. (2012). Canine parvovirus in asymptomatic canine felids. Vet. Microbiol. 157, 78–85. doi: 10.1016/j.vetmic.2011.12.024
Cotmore, S. F., Agbandje-McKenna, M., Chiorini, J. A., Gatherer, D., Mukha, D. V., Pintel, D. J., et al. (2013). Rationalization and Extension of the Taxonomy of the Family Parvoviridae. Available online at: http://www.ictvonline.org/proposals/2013.001a-aaV.A.vParvoviridae.pdf
Cotmore, S. F., and Tattersall, P. (2014). Parvoviruses: small does not mean simple. Annu. Rev. Virol. 1, 517–537. doi: 10.1146/annurev-virology-031413-085444
De Vries, M., Deijis, M., Canuti, M., van Schaik, B. D. C., Faria, N. R., van de Garde, M. D. B., et al. (2011). A sensitive assay for virus discovery in respiratory clinical samples. PLoS ONE 6:e16118. doi: 10.1371/journal.pone.0016118
De Vries, M., Oude Munnink, B. B., Deijis, M., Canuti, M., Koekkoek, S. M., Molenkamp, R., et al. (2012). Performance of VIDISCA-454 in feces-suspending and serum. Viruses 4, 1328–1334. doi: 10.3390/v4081328
Decaro, N., and Buonavoglia, C. (2012). Canine parvovirus-a review of epidemiological and diagnostic aspects, with emphasis on type 2c. Vet. Microbiol. 155, 1–12. doi: 10.1016/j.vetmic.2011.09.007
Deiss, V., Tratschin, J. D., Weitz, M., and Siegl, G. (1990). Cloning of the human parvovirus B19 genome and structural analysis of its palindromic termini. Virology 175, 247–254.
Dimm, M. W., Best, S. M., and Bloom, M. E. (2012). rtREV: an amino acid substitution matrix for inference of retrovirus and reverse transcriptase phylogeny. J. Mol. Evol. 55, 65–73. doi: 10.1007/s00239-001-2304-y
Donahue, R. E., Kessler, S. W., Bodine, D., McDonagh, K., Dunbar, C., Goodman, S., et al. (1992). Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J. Exp. Med. 176, 1125–1135.
Feichtinger, H., Li, S. L., Kaaya, E., Putkonen, P., Grünewald, K., Weyer, K., et al. (1992). A monkey model for Epstein Barr virus-associated lymphomagenesis in human acquired immunodeficiency syndrome. J. Exp. Med. 176, 281–286.
Felsenstein, J. (1981). Evolutionary trees from DNA sequences: a maximum likelihood approach. J. Mol. Evol. 17, 368–376.
Felsenstein, J. (1985). Confidence limits on phylogenies: an approach using the bootstrap. Evolution 39, 783. doi: 10.2307/2480678
Figgin, T., Varyali, N., Duru, F., and Kara, A. (2002). Parvovirus-B19 infection preceding acute myeloid leukemia with orbital granulocytic sarcoma. Leuk. Lymphoma 43, 2059–2061. doi: 10.1080/1042819021000016168
Friedrichs, K. R., and Young, K. M. (2008). Histiocytic sarcoma of macrophage origin in a cat: case report with a literature review of feline histiocytic malignancies and comparison with canine hemophagocytic histiocytic sarcoma. Vet. Clin. Pathol. 37, 121–128. doi: 10.1111/j.1939-165X.2008.00005.x
Fulmer, A. K., and Mauldin, G. E. (2007). Canine histiocytic neoplasia: an overview. Canine Pract. 41, 95–98.
Huson, D. H., Mitra, S., Ruscheweyh, H.-J., Weber, N., and Schuster, S. C. (2011). Phyl一致性树。J. Mol. Evol. 15, 485–505. doi: 10.1128/CMR.15.3.485-505.2002
Ibrahem, W. N., Hasony, H. J., and Hassan, J. G. (2014). Human parvovirus B19 in childhood acute lymphoblastic leukaemia in Basrah. J. Pak. Med. Assoc. 64, 9–12.
a new human coronavirus. Nat. Med. 10, 368–373. doi: 10.1038/nm1024

Vereide, D., and Sugden, B. (2009). Proof for EBV’s sustaining role in Burkitt’s lymphomas. Semin. Cancer Biol. 19, 389–393. doi: 10.1016/j.semcancer.2009.07.006

Walker, S. L., Wonderling, R. S., and Owens, R. A. (1997). Mutational analysis of the adeno-associated virus type 2 Rep68 protein helicase motifs. J. Virol. 71, 6996–7004.

Zádori, Z., Szélei, J., Lacoste, M.-C., Li, Y., Gariépy, S., Raymond, P., et al. (2001). A Viral phospholipase a2 is required for parvovirus infectivity. Dev. Cell 1, 291–302. doi: 10.1016/S1534-5807(01)00031-4

Zehender, G., De Maddalena, C., Canuti, M., Zappa, A., Amendola, A., Lai, A., et al. (2010). Rapid molecular evolution of human bocavirus revealed by Bayesian coalescent inference. Infect. Genet. Evol. 10, 215–220. doi: 10.1016/j.meegid.2009.11.011

Zhao, H., Zhao, L., Sun, Y., Qian, Y., Liu, L., Jia, L., et al. (2012). Detection of a bocavirus circular genome in fecal specimens from children with acute diarrhea in Beijing, China. PLoS ONE 7:e48980. doi: 10.1371/journal.pone.0048980

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 19 October 2014; paper pending published: 06 November 2014; accepted: 13 November 2014; published online: 01 December 2014.

Citation: Canuti M, Williams CV, Gadi SR, Jebbink MF, Oude Munnink BB, Jazaeri Farsani SM, Cullen JM and van der Hoek L (2014) Persistent viremia by a novel parvovirus in a slow loris (Nycticebus coucang) with diffuse histiocytic sarcoma. Front. Microbiol. 5:655. doi: 10.3389/fmicb.2014.00655

This article was submitted to Virology, a section of the journal Frontiers in Microbiology.

Copyright © 2014 Canuti, Williams, Gadi, Jebbink, Oude Munnink, Jazaeri Farsani, Cullen and van der Hoek. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.